search

Active clinical trials for "Hematologic Diseases"

Results 301-310 of 364

Exercise Following Autologous Peripheral Blood Stem Cell Transplantation

Hematological Disease

The study evaluates the effects of a supervised exercise program on the physical performance, the mood and the complications of therapy in patients undergoing a high-dose chemotherapy followed by an autologous peripheral blood stem cell transplantation.

Unknown status6 enrollment criteria

Effect of the Use of Simulation (Video) on the Oral Hygiene

"Hematologic Diseases"

The care of the oral cavity is an important way to prevent local and systemic infections. This study aimed to: evaluate the use of video as a teaching strategy of oral hygiene for patients undergoing chemotherapy. The methodological design used was quasi-experimental before-after intervention. The sample consisted of 23 subjects who performed the technique of oral hygiene before and after watching an educational video. To do so was given a kit with a toothbrush with soft bristles, toothpaste with low abrasivity, mouthwash or product to mouthwash and dental floss for oral hygiene. For data analysis we applied the parametric test t "Student" paired.

Unknown status8 enrollment criteria

Cardiac Coherence Combined With Personal Physical Activity in Patients With Cancer

Physical ActivityCancer1 more

APACCHE (Adapted Physical Activity and Cardiac Coherence in HEmatologic patients) study investigates effects of heart rate variability biofeedback training, combined with classical adapted physical activity, on health-related quality of life in patients previously treated for hematologic malignancies. It is a prospective, randomized clinical trial from University Hospital of Reunion Island. The main objective is evaluated with QLQ-C30 survey score differences.

Unknown status13 enrollment criteria

Exercise During Chemotherapy for Patients With Hematological Malignancies

Hematological DiseasesHematological Malignancies

The trial will evaluate the effects of aerobic exercise in patients undergoing chemotherapy for the treatment of a hematological neoplastic disease.

Unknown status5 enrollment criteria

WB-EMS and Nutrition in Patients With Hematological Malignancies

Hematologic DiseasesCachexia; Cancer4 more

This study evaluates the effects of a whole-body electromyostimulation (WB-EMS) training combined with individualized nutritional support on skeletal muscle mass, body composition, muscle strength/function, quality of life, fatigue, pain and gastrointestinal symptoms in patients with hematological malignancies 4-6 weeks before and 4-6 weeks after undergoing stem cell Transplantation. Within this context, this study also investigates the effect of the nutrition and exercise intervention on the period of hospitalization, period of White blood cell recovery and frequency and severity of complications (mucositis, Graft-versus-Host-Disease, infections) after stem cell Transplantation as consequences of the therapeutic immune Suppression.

Unknown status15 enrollment criteria

Observational Study of Home Administration of Carfilzomib

Multiple MyelomaHematologic Diseases

The purpose of this study is to evaluate the feasibility of an at home administration program for carfilzomib patients.

Withdrawn11 enrollment criteria

Impact of Early Implementation of Narrative Medicine Techniques on Patient Centered Attitudes of...

Narrative MedicineChronic Disease7 more

A qualitative study assessing the impact of early narrative medicine practice on Medical Honors Program (MHP) students' attitudes regarding patient-centered interactions, through interviewing patients with chronic or life-limiting illnesses to obtain their illness stories. MHP students will develop a patient narrative for the patients interviewed. These narratives will be edited by the patient, and, with the permission of the patients, may be published as a collection of stories.

Withdrawn18 enrollment criteria

Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid...

Hematologic DiseasesChronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a model of targeted therapy for human malignancies. Over the past decade, a broad array of drugs designed to selectively inhibit protein tyrosine kinases (PTK) [i.e., tyrosine kinase inhibitors, (TKI)] have emerged as novel therapies for cancer patients. Hence, CML is an hematopoietic stem cell disorder in which a t(9;22) (q34;q11) reciprocal chromosomal translocation gives rise to Philadelphia chromosome (Ph) and generates the BCR-ABL1 fusion gene encoding a constitutively activated PTK. TKIs, such as imatinib by blocking BCR-ABL1 kinase activity, selectively eradicate CML cells and induce durable responses and prolong survival. CML patients treated with TKI are monitored by quantitative RT-PCR to detect leukemic BCR-ABL1 transcript performed from peripheral blood samples (1). Since TKI treated CML patients have a near-normal life expectancy two important issues must be considered in the future: the quality of life and ethical aspects of a lifetime treatment, the budget impact for healthcare providers of treating patients during lifetime. One of the best ways to consider these two points is to ask the question about stopping TKI in good responder patients. We first reported a pilot study where imatinib was withdrawn in 12 CML patients treated and maintained in complete molecular remission (CMR), defined by undetectable residual disease (with sensitivity of 4.5 log) on quantitative RT-PCR, for at least two years. Then, we demonstrated in a multicenter study entitled STIM trial that imatinib could be safely discontinued in patients with CMR for at least 2 years (2). All molecular relapsing patients were sensitive when imatinib was re-challenged (3). Around 40% of these patients remain in a prolonged treatment-free remission (TFR) after treatment cessation (4). Taking into account the cost of imatinib and the number of months without treatment in STIM trial, the savings in France were estimated to be 9 million €. However, since only 40 % of patients are in treatment free remission, a study, assessing the real budget impact of stopping TKI in the eligible population seems necessary as no published study has ever addressed this question in France. Our aim is to assess the budget impact of discontinuing TKI treatment in patients with CML in deep molecular response since at least two years, compared with treatment during lifetime, from the French healthcare system point of view. This budget impact will be expressed as a "net benefit" and will be based on the difference between total costs incurred by this strategy and total costs avoided also. One of the originality of our study is to raise the issue of treatment cessation in the context of a chronic disease from an economic point of view. The other originality of this study is to use a decision model to perform this French budget impact analysis of TKI discontinuation, without setting up another trial. Besides the literature review and meta-analysis; the proposed probabilistic Markov model will use direct costs (including treatment costs and all health care related costs as well as costs related to relapse) extracted mainly from the French Health Insurance Databases.

Completed13 enrollment criteria

Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological...

MycosesLeukemia

This will be a retrospective study that includes retrospective chart reviews at major institutions across Canada. The intent of the study is to generate both regional and national incidence data for non-Candida invasive fungal infections (IFI) in high risk participants. The study will include participants receiving stem cell transplant and high dose chemotherapy treatment for leukemia.

Completed4 enrollment criteria

Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease

AnemiaSickle Cell1 more

To continue to follow the newborn cohort and the over-35 years of age cohort from the Cooperative Study of Sickle Cell Disease (CSSCD), a study of the natural history of sickle cell disease.

Completed1 enrollment criteria
1...303132...37

Need Help? Contact our team!


We'll reach out to this number within 24 hrs